abnormal kidney morphology, abnormal leukocyte adhesion, abnormal leukocyte physiology, abnormal lung thrombosis, abnormal pericardium morphology, abnormal placenta development, abnormal placental thrombosis, abnormal response to injury, abnormal thrombosis, abnormal trophoblast layer morphology, cardiac fibrosis, decreased body size, decreased circulating interleukin-6 level, decreased circulating tumor necrosis factor level, decreased sensitivity to induced morbidity/mortality, decreased spleen weight, decreased susceptibility to bacterial infection, decreased susceptibility to bacterial infection induced morbidity/mortality, decreased susceptibility to injury, decreased trophoblast giant cell number, decreased tumor necrosis factor secretion, embryonic growth arrest, embryonic lethality during organogenesis, complete penetrance, embryonic lethality during organogenesis, incomplete penetrance, embryonic lethality, complete penetrance, homeostasis/metabolism phenotype, increased circulating D-dimer level, increased circulating interleukin-1 beta level, increased circulating interleukin-6 level, increased circulating tumor necrosis factor level, increased heart right ventricle weight, increased heart weight, increased myocardial infarct size, increased sensitivity to induced morbidity/mortality, increased spleen weight, increased susceptibility to endotoxin shock, increased susceptibility to induced thrombosis, lethality during fetal growth through weaning, incomplete penetrance, lethality throughout fetal growth and development, incomplete penetrance, liver hemorrhage, lung hemorrhage, no abnormal phenotype detected, premature death, preweaning lethality, complete penetrance, preweaning lethality, incomplete penetrance, skin hemorrhage, slow postnatal weight gain, small ectoplacental cone